|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Sirion Therapeutics, Inc. |
| Information provided by: | Sirion Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT00502073 |
Purpose
The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.
| Condition | Intervention | Phase |
|
Dry Eye Syndromes |
Drug: cyclosporine |
Phase III |
| ChemIDplus related topics: | Cyclosporine Cyclosporin |
| Study Type: | Interventional |
| Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | ST-603-005 |
| First Received: | July 13, 2007 |
| Last Updated: | February 29, 2008 |
| ClinicalTrials.gov Identifier: | NCT00502073 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|